Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
Experiment 1
Subjects
- Location of subjects
- Netherlands
- Host species Species from which microbiome was sampled (if applicable)
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- antimicrobial agent antibiotic,antibiotics,Antibiotika,Antibiotikum,antibiotique,antimicrobial,antimicrobial agents,microbicide,microbicides,antimicrobial agent
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- control(no treatment)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- infants received short-term(<3days) antibiotic treatment
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- infants born between 32-42 weeks of gestation and admitted to the hospital level III neonatal intesive care or level II neonatal ward
- Group 0 sample size Number of subjects in the control (unexposed) group
- 28
- Group 1 sample size Number of subjects in the case (exposed) group
- 22
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Statistical test
- Kruskall-Wallis
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
Alpha Diversity
- Chao1 Abundance-based estimator of species richness
- unchanged
Signature 1
Source: Text
Description: Differences in gut microbiota composition between infants receiving no, short or long antibiotic treatment
Abundance in Group 1: increased abundance in infants received short-term(<3days) antibiotic treatment
NCBI | Links |
---|---|
Lactobacillus |
Revision editor(s): WikiWorks
Signature 2
Source: Text
Description: Differences in gut microbiota composition between infants receiving no, short or long antibiotic treatment
Abundance in Group 1: decreased abundance in infants received short-term(<3days) antibiotic treatment
NCBI | Links |
---|---|
Escherichia | |
Streptococcus |
Revision editor(s): WikiWorks
Experiment 2
Subjects
- Location of subjects
- Netherlands
- Host species Species from which microbiome was sampled (if applicable)
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- antimicrobial agent antibiotic,antibiotics,Antibiotika,Antibiotikum,antibiotique,antimicrobial,antimicrobial agents,microbicide,microbicides,antimicrobial agent
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- control(no treatment)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- infants received long-term(>5days) antibiotic treatment
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- infants born between 32-42 weeks of gestation and admitted to the hospital level III neonatal intesive care or level II neonatal ward
- Group 0 sample size Number of subjects in the control (unexposed) group
- 28
- Group 1 sample size Number of subjects in the case (exposed) group
- 13
Lab analysis
- Sequencing type
- 16S
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Statistical test
- Kruskall-Wallis
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
Alpha Diversity
- Chao1 Abundance-based estimator of species richness
- unchanged
Signature 1
Source: Text
Description: Differences in gut microbiota composition between infants receiving no, short or long antibiotic treatment
Abundance in Group 1: increased abundance in infants received long-term(>5days) antibiotic treatment
NCBI | Links |
---|---|
Lactobacillus | |
Enterococcus |
Revision editor(s): WikiWorks
Signature 2
Source: Text
Description: Differences in gut microbiota composition between infants receiving no, short or long antibiotic treatment
Abundance in Group 1: decreased abundance in infants received long-term(>5days) antibiotic treatment
NCBI | Links |
---|---|
Escherichia | |
Streptococcus |
Revision editor(s): WikiWorks